MorphoSys 20F 2023 Annual report | MPSYF Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: activin, AMR, anaemia, anticoagulant, appraising, array, asthenia, BaFin, Bahnhofstrasse, BidCo, Biegi, biomolecular, bleeding, Boerse, Broadway, bromodomain, burn, CERT, championed, condensed, conditionally, consummate, consummated, consummation, counteract, deadly, delisted, delisting, density, deregistration, dire, DPLTA, Dutch, Dynamic, element, Elm, erroneously, escrow, evolution, excitement, fiber, finanical, FISG, float, Fourteen, Gordon, Gynecologic, Haven, headache, headcount, Homolog, hotspot, IIT, imminent, IMP, impractical, incorrectly, IOC, ISIN, Kirchensteuer, Kynam, landmark, legacy, LP, lump, maplirpacept, mirror, monetization, monetize, monjuvi®, morale, MTD, NIST, NJ, nov, numerical, numerically, obesity, obsolescence, ODD, official, offsett, oversupply, overwhelming, Panmure, peak, pendency, Pillar, pilot, pLoT, PMN, popular, pre, Princeton, prudent, PTCL, questionnaire, recurrent, recycling, redefine, resilient, riskier, runway, sake, scrapping, sentiment, Seoul, sharpened, showcase, showcased, slightly, standalone, Stanley, Steueranmeldung, stratification, stroke, surprisingly, tableting, tactical, tafasistamab, Tim, uncapped, underscoring, ushered, vera, Visit, volunteer, Woodford, worse, Zeste, Zweigniederlassung

Removed: acute, ADCC, ADCP, age, aggressive, Alzheimer, Amsterdam, amyloid, antigen, antirheumatic, ATAD, atopic, axicabtagene, Baltimore, Basel, bayer, bi, Bochum, boehringer, brentuximab, Breyanzi, Castresana, chemotherapy, chimeric, CHOP, cognitive, commerce, compelling, Conceptual, constitutional, consumed, corticosteroid, Council, curative, cyclophosphamide, cytolytic, cytotoxicity, database, deemphasize, dementia, detected, DHAP, differentiated, diverse, doxorubicin, Dupilumab, emerge, Euronext, Fc, feasible, febrile, Fibron, figure, Finanzgericht, forfeiture, freely, Freie, gained, gantenerumab, GeneFrontier, generating, genetically, Genzyme, geographic, GlaxoSmithKline, grow, habilitated, Hamburg, Hanover, heightening, histone, Historically, homogeneously, ibrutinib, ICE, iloleucel, incl, ingelheim, instrumental, interposition, interrupting, Investmentsteuergesetz, Italy, Johnson, Kapitalbeteiligung, killer, killing, Kymriah, landscape, lengthier, LEO, lisocabtagene, lymphoblastic, Lyon, MA, Mainz, maraleucel, Maria, marketable, Maryland, matched, mdor, Merck, methotrexate, Micromet, mild, moderate, MSD, naked, observational, older, oncomed, OSCAR, Padova, para, parsaclisib, Pasteur, perpetual, phased, pixantrone, PK, plenum, polatuzumab, Polivy, Pratt, prednisone, ProChon, productivity, pulmonary, RA, reexamination, relapse, reliant, remission, restricting, resume, retrospective, rheumatoid, Rheumatology, Rowe, salvage, Sandoz, selection, ship, slower, Sosei, Spain, staffing, stepped, stipulating, suited, Tango, tisagenlecleucel, Toronto, trained, transformative, unconstitutional, uncured, unrelated, unscheduled, vedotin, vincristine, Wendy, Yescarta


1.			Constellation Pharmaceuticals, Inc. (USA)

2.			Constellation Securities Corp. (USA)

3.			MorphoSys US Inc. (USA)

MorphoSys (MPSYF) 20-F2023 FY Annual report (foreign)

Content analysis